Core Molding Technologies to Present and Host 1x1 Meetings at the 14th Annual East Coast IDEAS Conference on June 13, 2024
June 03, 2024 08:00 ET
|
Core Molding Technologies, Inc.
COLUMBUS, Ohio, June 03, 2024 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding,” “Core” or the “Company”), a leading engineered materials company specializing...
USI Insurance Services Launches PATH, a Proprietary Technology-Enabled Risk Control Platform
June 03, 2024 08:00 ET
|
USI Insurance Services
VALHALLA, N.Y., June 03, 2024 (GLOBE NEWSWIRE) -- USI Insurance Services (“USI”), a world leader in risk management, employee benefit and retirement plan consulting, today announced the launch of...
Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
June 03, 2024 08:00 ET
|
Cyclacel
CYCLACEL PHARMACEUTICALS REPORTS NEW CLINICAL DATA AT 2024 ASCO ANNUAL MEETING HIGHLIGHTING ORAL FADRACICLIB’S POTENTIAL AS A PRECISION MEDICINE FOR CANCER
Introducing the TimeProvider® XT Extension System for Migrating to a Modern Synchronization and Timing Systems Architecture
June 03, 2024 08:00 ET
|
Microchip Technology Inc.
CHANDLER, Ariz., June 03, 2024 (GLOBE NEWSWIRE) -- Critical infrastructure communication networks require highly accurate and resilient synchronization and timing, but over time these systems age...
AVRICORE HEALTH CORPORATE UPDATE – COMPANY ACHIEVES PROFITABILITY
June 03, 2024 08:00 ET
|
Avricore Health Inc.
Q1 2024 Results
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 03, 2024 08:00 ET
|
Replimune Group Inc
-- Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma demonstrate an overall response rate of 32.7% and duration of response...
PetMed Express, Inc. Announces Strategic Updates to Executive Leadership Team
June 03, 2024 08:00 ET
|
PetMed Express, Inc.
Caroline Conegliano appointed Chief Operating Officer Umesh Sripad appointed Chief Digital and Technology Officer Company Announces CFO transition DELRAY BEACH, Fla., June 03, 2024 (GLOBE...
Getty Realty Corp. Publishes 2024 Corporate Responsibility Report
June 03, 2024 08:00 ET
|
Getty Realty Corp.
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Getty Realty Corp. (NYSE: GTY) announced today that it has published its 2024 Corporate Responsibility Report highlighting the Company’s environmental,...
Apogee Minerals Announces Appointment of New Director
June 03, 2024 08:00 ET
|
Apogee Minerals Ltd.
Vancouver, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) -- Apogee Minerals Ltd. (“Apogee” or the “Company”) (TSXV: APMI) is pleased to announce the appointment of Mr. Nicholas Coltura as a...
Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
June 03, 2024 08:00 ET
|
Evaxion Biotech
Evaxion’s AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all assayed melanoma patientsFindings further confirm and validate the precision and...
- 03 juin 2024 07h30 HE Abcourt recoupe 91,8 g/t Au sur 0,5m à la mine Géant Dormant
- 02 juin 2024 10h00 HE Nanobiotix annonce de nouvelles données montrant un contrôle de la maladie et une réponse tumorale chez des patients traités avec NBTXR3 activé par radiothérapie suivi d’un anti-PD-1, comme traitement de deuxième intention ou plus, dans le cancer de la tête et du cou récurrent ou métastatique, naïf ou résistant aux anti-PD-1